Symptom relief in patients with reflux esophagitis: Comparative study of omeprazole, lansoprazole, and rabeprazole

Journal of Gastroenterology and Hepatology (Australia)

Volumn 18, Issue 12, 2003, Pages 1392-1398

  Adachi, Kyoichi ^a   Hashimoto, Tomoyuki ^b   Hamamoto, Naoharu ^c   Hirakawa, Kazuya ^d   Niigaki, Masatoshi ^e   Miyake, Tatsuya ^e   Taniura, Hiroyuki ^f   Ono, Masahiro ^d   Kaji, Takekazu ^d   Suetsugu, Hiroshi ^a   Yagi, Junko ^a   Komazawa, Yoshinori ^a   Mihara, Takafumi ^a   Katsube, Tomoko ^a   Fujishiro, Hirofumi ^a   Shizuku, Toshihiro ^c   Hattori, Shuzo ^b   Yamamoto, Shun ^c   Kinoshita, Yoshikazu ^a  

^a SHIMANE UNIVERSITY   (Japan)

^b Unnan General Hospital   (Japan)

^c Hirata Municipal Hospital   (Japan)

^d Shimane Adult Disease Center   (Japan)

^e Masuda Medical Association Hospital   (Japan)

^f Muikaichi Hospital   (Japan)

Author keywords

Comparative study; Lansoprazole; Omeprazole; Rabeprazole; Reflux esophagitis; Symptom relief

Indexed keywords

ACID; LANSOPRAZOLE; OMEPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; ENDOSCOPY; FEMALE; HEALING; HEARTBURN; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PATIENT; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; REFLUX ESOPHAGITIS; REMISSION; SCORING SYSTEM; SYMPTOMATOLOGY;

EID: 9144242617     PISSN: 08159319     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1746.2003.03190.x     Document Type: Article

References (30)

1. Ghillebert G, Demeyere AM, Janssens J, Vantrappen G. How well can quantitative 24-hour intraesophageal pH monitoring distinguish various degrees of reflux disease? Dig. Dis. Sci. 1995; 40: 1317-24.
2. Mittal RK, Holloway RH, Penagini R, Blackshaw LA, Dent J. Transient lower esophageal sphincter relaxation. Gastroenterology 1995; 109: 601-10.
3. Bell NJV, Hunt RH. Role of gastric acid suppression in the treatment of gastro-oesophageal reflux disease. Gut 1992; 33: 118-24.
4. Sachs G. Proton pump inhibitors and acid-related diseases. Pharmacotherapy 1997; 17: 22-37.
5. Jansen JB, Van Oene JC. Standard-dose lansoprazole is more effective than high-dose ranitidine in achieving endoscopic healing and symptom relief in patients with moderately severe reflux oesophagitis. The Dutch Lansoprazole Study Group. Aliment. Pharmacol. Ther. 1999; 13: 1611-20.
6. Kawano S, Murata H, Tsuji S et al. Randomized comparative study of omeprazole and famotidine in reflux esophagitis. J. Gastroenterol. Hepatol. 2002; 17: 955-9.
7. Besancon M, Simon A, Sachs G, Shin JM. Sites of reaction of the gastric H,K-ATPase with extracytoplasmic thiol reagents. J. Biol. Chem. 1997; 272: 22438-46.
8. Williams MP, Sercombe J, Hamilton MI, Pounder RE. A placebo-controlled trial to assess the effects of 8 days of dosing with rabeprazole versus omeprazole on 24-h intragastric acidity and plasma gastrin concentrations in young healthy male subjects. Aliment. Pharmacol. Ther. 1998; 12: 1079-89.
9. Williams MP, Pounder RE. Review article: the pharmacology of rabeprazole. Aliment. Pharmacol. Ther. 1999; 13 (Suppl. 3): 3-10.
10. Gardner JD, Perdomo C, Sloan S et al. Integrated acidity and rabeprazole pharmacology. Aliment. Pharmacol. Ther. 2002; 16: 455-64.
11. Saitoh T, Fukushima Y, Otsuka H et al. Effects of rabeprazole, lansoprazole and omeprazole on intragastric pH in CYP2C19 extensive metabolizers. Aliment. Pharmacol. Ther. 2002; 16: 1811-17.
12. Dimenas E. Methodological aspects of evaluation of Quality of Life in upper gastrointestinal diseases. Scand. J. Gastroenterol. 1993; 28 (Suppl. 199): 18-21.
13. Dimenas E, Carlsson G, Glise H, Israelsson B, Wiklund I. Relevance of norm values as part of the documentation of quality of life instruments for use in upper gastrointestinal disease. Scand. J. Gastroenterol. 1996; 31 (Suppl. 221): 8-13.
14. Enck P, Dubois D, Marquis P. Quality of life in patients with upper gastrointestinal symptoms: results from the Domestic/International Gastroenterology Surveillance Study (DIGEST). Scand. J. Gastroenterol. 1999; 34 (Suppl. 231): 48-54.
15. Farup C, Kleinman L, Sloan S et al. The impact of nocturnal symptoms associated with gastroesophageal reflux disease on health-related quality of life. Arch. Intern. Med. 2001; 161: 45-52.
16. Adachi K, Ishihara S, Hashimoto T et al. Efficacy of sucralfate for Helicobacter pylori eradication triple therapy in comparison with a lansoprazole-based regimen. Aliment. Pharmacol. Ther. 2000; 14: 919-22.
17. Adachi K, Ishihara S, Hashimoto T et al. Efficacy of ecabet sodium for Helicobacter pylori eradication triple therapy in comparison with a lansoprazole-based regimen. Aliment. Pharmacol. Ther. 2001; 15: 1187-91.
18. Hashimoto T, Adachi K, Ishimura N et al. Safety and efficacy of glucagon as a premedication for upper gastrointestinal endoscopy - a comparative study with butyl scopolamine bromide. Aliment. Pharmacol. Ther. 2002; 16: 111-18.
19. Lundell LR, Dent J, Bennett JR et al. Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut 1999; 45: 172-80.
20. Amano K, Adachi K, Katsube T, Watanabe M, Kinoshita Y. Role of hiatus hernia and gastric mucosal atrophy in the development of reflux esophagitis in the elderly. J. Gastroenterol. Hepatol. 2001; 16: 132-6.
21. Adachi K, Kawamura A, Ono M et al. Comparative evaluation of urine-based and other minimally invasive methods for the diagnosis of Helicobacter pylori infection. J. Gastroenterol. 2002; 37: 703-8.
22. Holtmann G, Bytzer P, Metz M, Loeffler V, Blum AL. A randomized, double-blind, comparative study of standard-dose rabeprazole and high-dose omeprazole in gastro-oesophageal reflux disease. Aliment. Pharmacol. Ther. 2002; 16: 479-85.
23. Bytzer P. On-demand therapy for gastro-oesophageal reflux disease. Eur. J. Gastroenterol. Hepatol. 2001; 13 (Suppl. 1): S19-22.
24. Johnsson F, Weywadt L, Solhaug JH, Hernqvist H, Bengtsson L. One-week omeprazole treatment in the diagnosis of gastro-oesophageal reflux disease. Scand. J. Gastroenterol. 1998; 33: 15-20.
25. Bate CM, Riley SA, Chapman RW, Durnin AT, Taylor MD. Evaluation of omeprazole as a cost-effective diagnostic test for gastro-oesophageal reflux disease. Aliment. Pharmacol. Ther. 1999; 13: 59-66.
26. Fass R., Ofman JJ, Sampliner RE, Camargo L, Wendel C, Fennerty MB. The omeprazole test is as sensitive as 24-h oesophageal pH monitoring in diagnosing gastro-oesophageal reflux disease in symptomatic patients with erosive oesophagitis. Aliment. Pharmacol. Ther. 2000; 14: 389-96.
27. Meier JH, McNally PR, Punja M et al. Does omeprazole (Prilosec) improve respiratory function in asthmatics with gastroesophageal reflux? A double-blind, placebo-controlled crossover study. Dig. Dis. Sci. 1994; 39: 2127-33.
28. Hanson DG, Kamel PL, Kahrilas PJ. Outcomes of antireflux therapy for the treatment of chronic laryngitis. Ann. Otol. Rhinol. Laryngol. 1995; 104: 550-5.
29. Harding SM, Richter JE, Guzzo MR, Schan CA, Alexander RW, Bradley LA. Asthma and gastroesophageal reflux: acid suppressive therapy improves asthma outcome. Am. J. Med. 1996; 100: 395-405.
30. Holtmann G, Cain C, Malfertheiner P. Gastric Helicobacter pylori infection accelerates healing of reflux esophagitis during treatment with the proton pump inhibitor pantoprazole. Gastroenterology 1999; 117: 11-16.